RCS - Ergomed plc - Ergomed plc collects Queen's Award for Enterprise <Origin Href="QuoteRef">ERGO.L</Origin>

ErgomedAnnouncement

06/09/2014 18:37

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20140721:nRSU8351Ma


RNS Number : 8351M
Ergomed plc
21 July 2014 
 
Press Release 
 
Ergomed plc announces that its drug safety business PrimeVigilance was awarded
a 2014 Queen's Award 
 
for Enterprise 
 
London, UK - 21 July 2014; Ergomed plc, a profitable UK-based company,
dedicated to the provision of specialised services to the pharmaceutical
industry and the development of new drugs, is pleased to announce that its
drug safety business PrimeVigilance, the specialist pharmacovigilance service
provider, has been awarded the Queen's Award for Enterprise 2014 in
Recognition of Substantial Growth and Commercial Success. Dr Miro Reljanovic,
CEO of Ergomed and Dr Elliot Brown co-founder of PrimeVigilance, collected the
award from the Queen at Buckingham Palace on 14 July 2014. 
 
PrimeVigilance received the accolade - which is the highest official award for
business success in the UK - in recognition of achieving substantial overseas
earnings with growth and commercial success for the last six years. 
 
Dr Miroslav Reljanovic, Chief Executive Officer of Ergomed, commented: "This
award is testament to the high quality service we provide to our customers
around the world.  The Queen's Award is a great honour not just for the
company but for all of our individual employees internationally who have
helped contribute to the company's success.  We look forward to building on
our success and achieving further growth in the future." 
 
The Queen's Awards for Enterprise is a prestigious awards programme for
British businesses and organisations that excel at trade, innovation or
sustainable development.  The awards are made annually by HM The Queen, and
are only given for the highest levels of excellence demonstrated in each
category. They are judged to a demanding level and winners receive a number of
benefits and worldwide recognition. 
 
Click on, or paste the following link into your web browser, to view the
associated PDF document. 
 
http://www.rns-pdf.londonstockexchange.com/rns/8351M_-2014-7-21.pdf 
 
**** 
 
Note to Editors: 
 
About Ergomed 
 
Founded in 1997, Ergomed Plc is a profitable UK-based company, providing drug
development services to the pharmaceutical industry and has a growing
portfolio of co-development partnerships. It operates in over 40 countries. 
 
Ergomed provides clinical development, trial management and pharmacovigilance
services to over 60 clients ranging from top 10 pharmaceutical companies to
small and mid-sized drug development companies. Ergomed successfully manages
clinical development from Phase I through to late phase programmes. 
 
Ergomed has a wide therapeutic focus, with a particular expertise in oncology,
neurology and immunology and the development of orphan drugs. Ergomed believes
its approach to clinical trials is differentiated from that of other providers
by its innovative Study Site Management model and the use of Study Physician
Teams, resulting in a close relationship between Ergomed and the physicians
involved in clinical trials. 
 
As well as providing high quality clinical development services, Ergomed is
building a portfolio of co-development partnerships with pharma and biotech
companies which share the risks and rewards of drug development. Ergomed
leverages its expertise and services in return for carried interest in the
drugs under development.  For further information, visit:
http://ergomedgroup.com 
 
About PrimeVigilance 
 
The pharmacovigilance (PV) services offered by PrimeVigilance cover all the
regulatory and scientific elements of PV required to obtain and maintain
product licences for medicines within Europe: Qualified Person, Risk
Management Planning (RMP), and a compliant PV System with consistent Adverse
Event data capture, robust Quality Management, expedited reporting,
preparation of Periodic Safety Update Reports, literature screening, safety
signal detection and evaluation, benefit-risk assessment, compliance auditing,
support during crisis and various ad hoc assignments. PrimeVigilance also
offers fully integrated international Medical Information services. 
www.primevigilance.com 
 
For further information: 
 
Hume Brophy 
 
Mary Clark, Supriya Mathur, Hollie Vile 
 
Phone: + 44 203 440 5654 
 
E-mail: ergomed@humebrophy.com 
 
This information is provided by RNS
The company news service from the London Stock Exchange